Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report

Alessandro Inno; Fabiana Marchetti; Matteo Valerio; Niccolò Giaj Levra; Filippo Alongi; Giovanni Foti; Stefania Gori

doi:10.33393/dti.2023.2593

Authors

Alessandro Inno Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy https://orcid.org/0000-0001-6331-6908
Fabiana Marchetti Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy
Matteo Valerio Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy https://orcid.org/0000-0001-9156-4941
Niccolò Giaj Levra Advanced Radiation Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy
Filippo Alongi Advanced Radiation Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy
Giovanni Foti Radiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy
Stefania Gori Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy https://orcid.org/0000-0001-6320-405X

DOI:

https://doi.org/10.33393/dti.2023.2593

Keywords:

Brain metastases, Central nervous system, KRAS, NSCLC, Sotorasib

Abstract

In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and the activity of sotorasib in the setting of brain metastases should be further investigated. Here we report the case of a KRAS p.G12C mutant NSCLC patient with three brain metastases, of whom one was untreated and the other two had progressed after radiotherapy with symptoms requiring steroids, that responded to sotorasib. Our report suggests that sotorasib may be active against untreated or progressive brain metastases, supporting further evaluation of sotorasib in this setting.

Downloads

Download data is not yet available.

References

Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. https://doi.org/10.1016/S0140-6736(21)00312-3 PMID:34273294 DOI: https://doi.org/10.1016/S0140-6736(21)00312-3

Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. https://doi.org/10.1056/NEJMoa2103695 PMID:34096690 DOI: https://doi.org/10.1056/NEJMoa2103695

Inno A, Di Noia V, D’Argento E, Modena A, Gori S. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(6):599-609. https://doi.org/10.21037/tlcr.2016.11.01 PMID:28149755 DOI: https://doi.org/10.21037/tlcr.2016.11.01

Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;JCO2018783118(33):JCO2018783118. https://doi.org/10.1200/JCO.2018.78.3118 PMID:30153097 DOI: https://doi.org/10.1200/JCO.2018.78.3118

Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29(11):2214-2222. https://doi.org/10.1093/annonc/mdy405 PMID:30215676 DOI: https://doi.org/10.1093/annonc/mdy405

Lamberti G, Aizer A, Ricciuti B, et al. Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRASG12C-mutant non-small-cell lung cancer. JCO Precis Oncol. 2023;7(7):e2200621. https://doi.org/10.1200/PO.22.00621 PMID:36809054 DOI: https://doi.org/10.1200/PO.22.00621